Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bendavia (MTP-131) in Heart Failure with Reduced LVEF
NCT02388529Phase 1Withdrawn
- Sponsor
- Stealth BioTherapeutics
- Start
- May 2015
- Primary completion
- Sep 2015
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of elamipretide in heart failure with reduced ejection fraction (HFrEF) (4 arms), sponsored by Stealth BioTherapeutics. Primary endpoints: Incidence of Adverse Events at Day 33 and Mean peak plasma concentration of MTP-131 at Day 12. Planned start May 2015; status: withdrawn.
02
Drugs
elamipretide
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NCT02388529.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02388529.